BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34939129)

  • 1. Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma.
    Dejonckheere CS; Böhner AMC; Koch D; Schmeel LC; Herrlinger U; Vatter H; Schneider M; Schuss P; Giordano FA; Köksal MA
    Strahlenther Onkol; 2022 May; 198(5):468-474. PubMed ID: 34939129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
    Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
    J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
    Butowski N; Chang SM; Lamborn KR; Polley MY; Pieper R; Costello JF; Vandenberg S; Parvataneni R; Nicole A; Sneed PK; Clarke J; Hsieh E; Costa BM; Reis RM; Hristova-Kazmierski M; Nicol SJ; Thornton DE; Prados MD
    Neuro Oncol; 2011 Dec; 13(12):1331-8. PubMed ID: 21896554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
    Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
    Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
    Yu Z; Zhou Z; Xu M; Song K; Shen J; Zhu W; Wei L; Xu H
    Comput Math Methods Med; 2023; 2023():1553408. PubMed ID: 36756387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
    Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
    J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
    Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
    J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
    Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
    J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and survival characteristics of primary and secondary gliosarcoma patients.
    Amer A; Khose S; Alhasan H; Pokhylevych H; Fuller G; Chasen N; de Groot J; Johnson JM
    Clin Neurol Neurosurg; 2022 Mar; 214():107146. PubMed ID: 35101778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
    Zhang Y; Ma JP; Weng JC; Wang L; Wu Z; Li D; Zhang JT
    Neurosurg Rev; 2021 Apr; 44(2):1003-1015. PubMed ID: 32189095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.